Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) Insider Sells $136,611.18 in Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Yu-Waye Chu sold 21,279 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $136,611.18. Following the completion of the transaction, the insider directly owned 189,446 shares of the company’s stock, valued at approximately $1,216,243.32. The trade was a 10.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

CytomX Therapeutics Stock Performance

NASDAQ CTMX opened at $4.45 on Friday. The firm’s fifty day moving average price is $5.28 and its two-hundred day moving average price is $4.13. The stock has a market cap of $757.35 million, a PE ratio of -111.25 and a beta of 2.44. CytomX Therapeutics, Inc. has a fifty-two week low of $0.40 and a fifty-two week high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings results on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. As a group, sell-side analysts predict that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on CTMX shares. Oppenheimer reissued an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a research note on Monday, March 16th. Guggenheim upped their price objective on CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings lowered shares of CytomX Therapeutics from a “hold (c-)” rating to a “sell (d)” rating in a report on Thursday. Cantor Fitzgerald lifted their target price on shares of CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 4th. Finally, JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $7.00 to $12.00 in a report on Monday, March 16th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $13.22.

CytomX Therapeutics News Roundup

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

Institutional Investors Weigh In On CytomX Therapeutics

Institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC increased its stake in shares of CytomX Therapeutics by 4.5% in the fourth quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 2,169 shares during the period. Wells Fargo & Company MN lifted its stake in shares of CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 3,000 shares during the period. Velan Capital Investment Management LP lifted its stake in shares of CytomX Therapeutics by 6.7% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock worth $255,000 after acquiring an additional 5,000 shares during the period. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics in the third quarter valued at approximately $25,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in CytomX Therapeutics in the fourth quarter valued at approximately $35,000. Institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.